Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences)(Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences))

概要

基本信息

药物类型

预防性疫苗

别名

GPO Avian Flu Vaccine、Influenza A virus vaccine H5N2 intranasal、Intranasal H5N2 vaccine

+ [4]

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

流感病毒感染

非在研适应症-

原研机构

Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences

在研机构

Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences

非在研机构-

最高研发阶段批准上市

首次获批日期

俄罗斯 (2012-11-28),

流感病毒感染

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

3

项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的临床试验

NCT02153671 / Completed临床2期IIT

Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects

This study is designed to assess whether a live attenuated Influenza vaccine (LAIV) can induce a long-lasting immune memory by comparing the immunologic response to two doses of the OrniFlu® inactivated vaccine given to subjects previously primed with LAIV and subjects who did not received LAIV.

开始日期2014-05-01

申办/合作机构

Program for Appropriate Technology in Health

[+2]

NCT01982331 / Completed临床1期IIT

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/California/66/395 (H2N2)Influenza Vaccine

This is a phase I study to evaluate the safety of a vaccine to protect against influenza viruses of the H2N2 subtype. A total of 40 adults will be enrolled and receive two doses of vaccine or placebo one month apart.

开始日期2013-10-01

申办/合作机构

Program for Appropriate Technology in Health

[+2]

NCT01719783 / Completed临床1期IIT

Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine

To evaluate the safety profile of two intranasal doses of LAIV A/17/turkey/Turkey/05/133 (H5N2) in healthy adults.

开始日期2012-09-01

申办/合作机构

Program for Appropriate Technology in Health

[+2]

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的临床结果

登录后查看更多信息

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的转化医学

登录后查看更多信息

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的专利（医药）

登录后查看更多信息

76

项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的文献（医药）

2022-12-01·Animal Diseases

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs

Article

作者: Artiaga, Bianca L ; Morozov, Igor ; Indran, Sabarish V ; Henningson, Jamie ; Ransburgh, Russell ; De Carvalho Madrid, Darling Melany ; Balaraman, Velmurugan ; Gu, Weihong ; Driver, John P ; Richt, Jürgen A ; Kwon, Taeyong ; Ma, Wenjun

AbstractNatural killer T (NKT) cells activated with the glycolipid ligand α-galactosylceramide (α-GalCer) stimulate a wide variety of immune cells that enhance vaccine-mediated immune responses. Several studies have used this approach to adjuvant inactivated and subunit influenza A virus (IAV) vaccines, including to enhance cross-protective influenza immunity. However, less is known about whether α-GalCer can enhance live attenuated influenza virus (LAIV) vaccines, which usually induce superior heterologous and heterosubtypic immunity compared to non-replicating influenza vaccines. The current study used the swine influenza challenge model to assess whether α-GalCer can enhance cross-protective immune responses elicited by a recombinant H3N2 LAIV vaccine (TX98ΔNS1) encoding a truncated NS1 protein. In one study, weaning pigs were administered the H3N2 TX98ΔNS1 LAIV vaccine with 0, 10, 50, and 100 μg/kg doses of α-GalCer, and subsequently challenged with a heterologous H3N2 virus. All treatment groups were protected from infection. However, the addition of α-GalCer appeared to suppress nasal shedding of the LAIV vaccine. In another experiment, pigs vaccinated with the H3N2 LAIV, with or without 50 μg/kg of α-GalCer, were challenged with the heterosubtypic pandemic H1N1 virus. Pigs vaccinated with the LAIV alone generated cross-reactive humoral and cellular responses which blocked virus replication in the airways, and significantly decreased virus shedding. On the other hand, combining the vaccine with α-GalCer reduced cross-protective cellular and antibody responses, and resulted in higher virus titers in respiratory tissues. These findings suggest that: (i) high doses of α-GalCer impair the replication and nasal shedding of the LAIV vaccine; and (ii) α-GalCer might interfere with heterosubtypic cross-protective immune responses. This research raise concerns that should be considered before trying to use NKT cell agonists as a possible adjuvant approach for LAIV vaccines.

2022-11-01·Vaccine

Reverse genetics based H5N2 vaccine provides clinical protection against H5N1, H5N8 and H9N2 avian influenza infection in chickens

Article

作者: Bhatia, Sandeep ; Kalaiyarasu, Semmannan ; Bhandari, Nisha ; Sood, Richa ; Panickan, Sivasankar ; Tripathi, Meghna ; Pateriya, Atul Kumar ; Bhat, Sushant

The current study aimed to develop broadly protective vaccines for avian influenza. In an earlier study, HA stalk (universal flu vaccine) was found to be broadly protective against different subtypes of influenza virus in mice. Hence, we were interested to know its breadth of protective efficacy either alone or combined with inactivated rgH5N2 (clade 2.3.2.1a) vaccine against challenge viruses of homologous H5N1, heterologous H5N8 (clade 2.3.4.4) and heterosubtypic H9N2 virus in specific pathogen-free chickens. The rgH5N2 vaccine alone or in combination with HA stalk elicited sufficient pre-challenge immunity in the form of haemagglutination inhibiting (HI) antibodies and neutralizing antibodies (MNT) against H5N1, H5N8, and H9N2 in chickens. The rgH5N2 vaccine alone or in combination with HA stalk also attenuated the shedding of H5N1, H5N8 and H9N2 in chickens and protected against the lethal challenge of H5N1 or H5N8. In contrast, all HA stalk immunised chickens died upon H5N1 or H5N8 challenge and H9N2 challenged chickens survived. Our study suggests that the rgH5N2 vaccine can provide clinical protection against H5N1, H5N8 and can attenuate the viral shedding of H9N2 in chickens.

2021-07-01·Virus Research3区 · 医学

Evaluation of influenza A and B cold-adapted reassortant virus reproduction in trivalent live influenza vaccines

3区 · 医学

Article

作者: Rudenko, L G ; Desheva, Y A ; Landgraf, G

BACKGROUNDThe objective of the present study was to compare reproduction of trivalent LAIV vaccine strains in MDCK cells and to perform quantitative RT-PCR analysis of trivalent LAIV replication after inoculation in mice.METHODSWe applied a reverse transcriptase real-time PCR (rRT-PCR) analysis using TaqMan technique to evaluate the infectious titers of vaccine strains containing in trivalent live influenza vaccines (LAIVs). We confirmed the PCR data in ELISA using staining of MDCK monolayer with mouse monoclonal antibodies to hemagglutinin.RESULTSThe viral load during the reproduction of mono-vaccines and trivalent LAIV in MDCK cells was similar at low dilutions. The content of vaccine viruses was evaluated using quantitative RT-PCR analysis in the nasal turbinate and lungs of CBA mice on day 3 after intranasal immunization. It was shown that despite the almost complete absence of reproduction of the A/H3N2 virus in mice, the immune response of A/H3N2-specific antibodies was formed at the same level as to other viruses. In MDCK cells, a decreased infectious titers of vaccine viruses in trivalent LAIV compared to mono-vaccines was demonstrated except for B/Yamagata virus.CONCLUSIONRT-PCR analysis is applicable to assess the growth characteristics of cold-adapted reassortant influenza viruses in vitro and in mice. The interference of trivalent LAIV vaccine viruses in MDCK cells was minimal at low dilutions. In mice, decrease in infectious titers did not lead to a decline of the immunogenicity.

100 项与 Influenza A virus vaccine H5N2 intranasal(Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	俄罗斯	Institute Of Experimental Medicine Of The Russian Academy Of Medical Sciences	2012-11-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02153671 (CTgov)	临床2期	流感病毒感染	43	A(H5N1) inactivated influenza vaccine+aluminum hydroxide+A(H5N2) live attenuated influenza vaccine (LAIV) (H5N2 Primed)	範艱襯積壓構鏇齋願蓋(襯襯鬱鏇窪製淵餘積廠) = 製顧膚衊淵醖獵夢糧壓廠選餘觸鏇廠齋鹹膚顧 (繭艱鹽醖淵窪構願範繭, 壓鹹範襯壓窪鏇膚築膚 ~ 鹽積簾鏇醖窪繭衊鬱淵) 更多	-	2019-02-18
				aluminum hydroxide (Control)	範艱襯積壓構鏇齋願蓋(襯襯鬱鏇窪製淵餘積廠) = 觸壓淵積夢餘糧構窪憲廠選餘觸鏇廠齋鹹膚顧 (繭艱鹽醖淵窪構願範繭, 積構繭糧製選選鹹築鬱 ~ 膚糧廠窪網築夢積觸夢) 更多
NCT01982331 (CTgov)	临床1期	流感病毒感染	38	LAIV H2N2 (LAIV H2N2 Vaccine)	網夢製憲構窪鏇鹽夢積(鹽製鬱艱範糧窪繭餘願) = 顧襯築遞獵淵鏇衊憲網遞觸顧顧鬱遞觸鏇淵築 (築願鑰鑰夢網積範繭蓋, 艱選網鏇鏇遞鬱夢鏇獵 ~ 範憲廠膚網餘夢鑰鏇願) 更多	-	2019-02-06
				Placebo (Placebo)	網夢製憲構窪鏇鹽夢積(鹽製鬱艱範糧窪繭餘願) = 願醖觸衊齋廠鑰製選壓遞觸顧顧鬱遞觸鏇淵築 (築願鑰鑰夢網積範繭蓋, 積淵範積廠艱夢蓋淵憲 ~ 膚夢選鹹願構遞簾鹽衊) 更多
IAS2004	N/A	HIV感染	-	GPO-VIR	(網艱鏇襯壓餘壓鹽築壓) = Adverse events (rash, hepatitis, and nausea/vomiting) were found in 13 (14%) patients. 壓鹹蓋築醖築鹽製觸築 (膚憲鏇鬱鹹範製壓觸鑰 )	-	2004-01-01